iRhythm price target raised to $167 from $130 at Citi

Citi analyst Joanne Wuensch raised the firm’s price target on iRhythm (IRTC) to $167 from $130 and keeps a Buy rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.